Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head trial.
July 2, 2026 07:13 AM EDT
R&DPharma
Anna Brown
News Reporter
Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head trial. Full data haven’t yet emerged …
(Bloomberg) -- Roche Holding AG’s experimental lung cancer pill outperformed two approved medicines in a late-stage study,…
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung…
Swiss pharmaceutical and diagnostics giant Roche announced the success of a pivotal clinical trial for its drug divarasib in the…
Back in March, Roche revealed that its breast cancer pill had failed in a pivotal Phase 3 trial. Data presented at ASCO reveal…
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug…
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
Roche claims clinical trial success for lung cancer drug
